Since the laparoscopic cholecystectomy procedure was first introduced in Japan in 1990, its popularity has soared, as has its applicability for diseases. Indeed, its use during operations has transformed and even revolutionised the approach taken to conventional surgery. As well as boosting QOL (Quality of Life) among patients (easing pain, shortening hospitalisation and promoting an early recovery, etc.), its scope to shorten the treatment period required has earned it the title of ‘the perfect surgery’, since it also allows savings on medical expenses incurred.

     A small hole – around 5 mm to 2 cm in size – is drilled in the stomach with endoscopic surgery, via which an endoscope and a narrow surgical instrument are inserted and surgery performed. All of which means far less post-surgical pain when this approach is used compared to conventional surgery, while recovery is faster. This is also why it is recognised as minimally invasive (body-friendly) surgery.

     Although current applications mainly on cholelithiasis, choledocholithiasis, colon cancer, gastric cancer and inguinal hernias among others, the scope of treatable diseases is growing ever wider. Alongside these efforts, progress continues apace with forceps offering higher precision and functionality and the development of instruments including complex functions, e.g. allowing ligation, incision and grasping of objects.

     We have successfully mass produced range of surgical instruments, on the world’s leading medical forceps, which conventional machining would be unable to achieve.

     It is said, chucking becomes more difficult in machining operations for recent spearheading medical forceps production. However, in MIM production, it is not required any chucking, thus it lead stable mass production. 

     Our µ-MIM technology has employed for endoscopic surgery instruments mass production since we can respond the requirements of high precision, complex design, material and quantity assurance. (ISO 13485  May 2019)